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Background & Aims: Hepatocyte polarity is essential for the development of bile 
canaliculi and transport of bile and waste products such as copper safely out of the 
liver. Genetically inherited defects in polarized processes can cause severe diseases. 
Functional studies of autologous mutated proteins in the context of the polarized 
hepatocyte have been challenging because of the lack of appropriate cell models. 
The aim of this study was to obtain a patient–specific hepatocyte model that 
recapitulated hepatocyte polarity and to employ this model to study endogenous 
mutant proteins in liver diseases that involve hepatocyte polarity. Methods: Patients’  
and control subjects’ urine cell-derived pluripotent stem cells were differentiated 
towards hepatocyte-like cells. Results: Polarized hepatocyte-like cells (hiHeps) that 
formed in vivo-like bile canaliculi could be generated from embryonic and patient 
urine cell-derived pluripotent stem cells. HiHeps recapitulated polarized protein 
trafficking processes, exemplified by the Cu2+-induced redistribution of the copper 
transporter protein ATP7B to the bile canalicular domain. We demonstrated that, in 
contrast to the current dogma, the most frequent yet enigmatic Wilson disease-
causing ATP7B-H1069Q mutation per se did not preclude trafficking of ATP7B to the 
trans-Golgi Network. Instead, it prevented its Cu2+-induced polarized redistribution to 
the bile canalicular domain, unrepairable by pharmacological folding chaperones. 
Finally, we demonstrate that hiHeps from a MEDNIK disease patient suffering from 
liver copper overload of unclear etiology showed no defect in the Cu2+-induced 
redistribution of ATP7B to the bile canaliculi. Conclusions: Functional cell polarity 
can be achieved in patient pluripotent stem cell-derived hepatocyte like cells, and 




pathogenesis and drug responses for diseases where hepatocyte polarity is a key 
aspect.    
 
Lay summary 
This study demonstrates that cells that are isolated from urine can be reprogrammed 
in a dish towards hepatocytes that display architectural characteristics similar as 
seen the intact liver. The application of this methodology to cells from patients 
diagnosed with inherited copper metabolism-related liver diseases (that is, Wilson 
disease and MEDNIK syndrome) revealed unexpected and novel insights into patient 






Hepatocytes are polarized cells, exemplified by the segregation of their plasma 
membranes into basolateral/sinusoidal and apical/canalicular domains [1,2]. 
Hepatocyte polarity is essential for many hepatocyte-specific functions [1]. Not 
surprisingly therefore, loss of hepatocyte polarity is correlated with liver diseases [2]. 
In inherited liver diseases, mutations in specific genes can cause a defect in the 
targeting, expression and/ or function of proteins that display a steady state 
residence at either sinusoidal or canalicular surface domain [2].  
Some proteins adopt a polarized distribution in hepatocytes only under specific 
circumstances. For example, the copper transporter protein ATP7B normally resides 
in the trans-Golgi Network (TGN) but when intracellular copper levels become too 
high ATP7B displays a polarized translocation to the bile canalicular domain where 
excess copper is excreted [3,4]. Mutations in the ATP7B gene in patients with Wilson 
disease (WD) [5] lead to excess copper deposition and damage to the liver and brain 
[6]. Some mutations have been reported to impair the intracellular trafficking of the 
mutant ATP7B protein [7,8]. However, for several, including the frequent H1069Q 
mutation in the Caucasian WD population [9], their impact on the polarized trafficking 
of the mutant ATP7B to the bile canalicular domain in response to excess copper is 
unknown. Similarly, the impact of mutations in the traffic regulatory gene AP1S1 on 
the trafficking of ATP7B in hepatocytes of patients with MEDNIK syndrome, a 
disease with parallels to WD [10] has been postulated but not experimentally 
addressed.     
Patients’ biopsies provide information about the steady-state distribution of mutant 
proteins, but not about the regulated dynamics of mutant proteins such as the 




proteins including WD ATP7B mutants required their heterologous overexpression 
[11–14] in cancer cell lines, a strategy with several drawbacks [15]. Therefore, there 
is an urgent need for a cell culture system that recapitulates the trafficking of 
endogenously expressed mutant proteins in polarized human hepatocytes. Patient-
own cells are the ideal source to study endogenous mutant proteins. The ability to 
generate induced pluripotent stem cells (iPSC) from patients’ cells and to differentiate 
these to hepatocytes has been a major step towards the study of endogenous mutant 
proteins, including ATP7B, in physiologically relevant cell types [16–24]. However, 
the potential of iPSC-derived hepatocytes to polarize and form bile canaliculi, and 
their potential to study the polarized trafficking of endogenously expressed mutant 
protein, is not known.    
Here, we characterized the potential of human pluripotent stem cell-derived 
hepatocytes to develop apical-basal polarity, bile canaliculi, and recapitulate 
polarized trafficking processes. We investigated their potential to study the 
functionalities of endogenous mutant proteins in human diseases where hepatocyte 
polarity is a key aspect, in this case the copper-stimulated redistribution of (mutant) 
ATP7B to the bile canalicular domain. This study reveals unexpected results with 







Materials and methods 
Generation of induced pluripotent stem cells  
WD iPSC cells from the homozygous patient were generated as described previously 
[25].  WD iPSC cells from the heterozygous patient were generated from urine-
derived cells [26]. Informed consent was obtained from all subjects. Briefly, at 75% 
confluence, urine-derived cells were transduced with the lentiviral vector 
pRRL.PPT.SF.hOct34co.hKlf4co.hSox2co.hmyc.idTomato.pre.FRT (Supplementary 
CTAT Table). After two days cells were transferred to vitronectin-coated 
(ThermoFisher) vessels and cultured in Essential-6 medium (ThermoFisher) with 
10ng/ml FGF. When nascent iPSC colonies appeared, medium was switched to 
Essential-8 medium (ThermoFisher) for colony expansion. After two weeks, iPSC 
colonies were isolated and cultured for >6 passages.  
 
Embryoid body formation assay 
Embryoid bodies (EB) were generated by detaching iPSC colonies with 0.5mM EDTA 
in PBS. Aggregates were transferred to Ultra-Low attachment flasks (Corning) and 
cultured in Essential-8 overnight. EB’s were cultured in KnockOut™ Serum-
Replacement-medium (ThermoFisher) for 10d. Then, EB were transferred to hESC-
qualified matrigel (BD/Biosciences)-coated coverslips and cultured for another 4d in 
KnockOut™SR. EB were fixed in 4% paraformaldehyde and immunohistochemically 
analyzed. 
 




All human pluripotent stem cell lines (Supplementary CTAT Table) were maintained 
on Vitronectin in Essential-8.  Cells were passaged every 4-5d with 1% RevitaCell 
Supplement added overnight on the day of passage. 
 
Hepatocyte differentiation 
50,000 iPSC were plated as single cells in a vitronectin-coated (ThermoFisher) well 
and cultured in Essential-8 with RevitaCell supplement. Next day, cells were 
differentiated to definitive endoderm using the PSC Definitive-Endoderm-Induction Kit 
(ThermoFisher). After 2d, RPMI1640 (ThermoFisher) containing 20ng/ml BMP4, 
10ng/ml FGF2, 0.5% DMSO (Sigma) and B27-supplement (ThermoFisher) was 
added for 5d for hepatic lineage specification. The hepatic progenitor cells were then 
transferred to ESC-qualified Matrigel-coated wells in RPMI1640 with 20ng/ml HGF, 
0.5% DMSO and B27-supplement, with 1% RevitaCell supplement on the first day. 
Next day cells were overlaid with a ESC-qualified Matrigel and cultured for 5 more 
days. To promote further maturation, cells were cultured in Lonza HCM/Bulletkit 
medium with 20ng/ml Oncostatin-M, known to stimulate hepatocyte polarity 
development [27]. Medium was changed daily for all stages of differentiation. For 
ATP7B translocation experiments, mature hiHeps were treated with 200µM BCS 
(Sigma) for 8h, washed with PBS, and treated with 200µM BCS or 100µM CuSO4 for 
16h. For CFDA transport assay, hiHeps were incubated with 0.5μM CFDA (Sigma-
Aldrich) at 37°C for 30min and analyzed with a Leica DMI 6000 fluorescent 
microscope. To asses LDL uptake, hiHeps were incubated with 10µg/ml DiI-LDL 
(Alfa-Aesar) for 4h, washed, fixed in 4% paraformaldehyde for 20min, stained with 
DAPI and mounted. For chemical chaperone rescue experiments, hiHeps were 





Western blotting  
Cell lysates were prepared in RIPA buffer (150 mM NaCl, 1% NP-40, 0,5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris pH 8,0) with protease inhibitors, and mixed 1:1 
with sample buffer (2% SDS, 5% β‐mercaptoethanol, 0.125 M Tris–HCl, pH 6.8,  40% 
glycerol, 0,01% bromophenolblue) and incubated at 70°C for 10 min. Proteins were 
resolved by SDS-PAGE and electrotransferred onto PVDF membranes. Membranes 
were blocked with Odyssey blocking buffer and incubated with primary antibodies 
(Supplementary CTAT Table). Membranes were washed, incubated with fluorescently 
labeled secondary antibodies, and scanned with the Odyssey. Relative quantification 
was performed using the Odyssey software. 
 
Microscopy 
Immunolabeling was done as described previously [28]. For antibodies see 
Supplementary CTAT Table. Fluorescent images were captured on a Leica DMI 6000 
fluorescent microscope and a Leica SP8 DMI 6000 confocal microscope, and 
analyzed using ImageJ and Adobe Photoshop. Quantification of colocalization in 
high-resolution confocal images was done using ImarisColoc software. Thresholds 
were set using the ImarisColoc automatic thresholding algorithm. Electron 
microscopy was performed as described previously [29]. 60nm sections imaged with 
a Zeiss Supra55 in STEM mode at 26KV using an external scan generator (Fibics, 
Canada) yielding mosaics of large area scans at 2.5nm pixel resolution.   
 




RNA was collected using TRI reagent (Sigma). Total RNA was reverse transcribed in 
the presence of oligo(dT)12–18 (Invitrogen) and dNTPs (Invitrogen) with M-MLV 
reverse transcriptase (Invitrogen) according to manufacturer’s instructions. Gene 
expression levels were measured by real-time quantitative RT-PCR with ABsolute 
QPCR SYBR Green Master Mix (Westburg) in a Step-One Plus RTPCR apparatus. 
Resulting data analyzed using the LinRegPCR method. See supplementary 







Differentiation of pluripotent stem cells to hepatocyte-like cells 
Pluripotent HUES9 cells were differentiated toward hepatocyte-like cells (hiHeps) 
using a protocol based on embryonic hepatic development and previous studies on 
hepatocyte differentiation in culture [16,24,30] (Figure 1A). Differentiation resulted in 
the loss of expression of pluripotency markers and progressive expression of hepatic 
marker proteins, including hepatocyte nuclear factor (HNF)4-alpha, alpha-fetoprotein 
and albumin (Figure 1B and 2B), glutamate-ammonia ligase and carbamoyl-
phosphate synthetase-1, sodium-taurocholate cotransporting polypeptide (NTCP), 
and alpha-1-antitrypsin (AAT) (Figure 2A). Virtually all AAT-positive HiHeps were 
positive for HNF4a and most HNF4a-positive cells were positive for AAT 
(Supplemental Figure S1A). Fluorescently labeled low-density lipoprotein was 
endocytosed in hiHeps (Figure 2A). Electron-microscopy showed copious quantities 
of glycogen in the hiHeps’ cytosol (Figure 2C). Cholangiocyte markers were absent 
from hiHeps (supplemental Figure S1B). The differentiation yield, based on the 
percentage of AAT- or HNF4a-expressing HiHeps, was ~50% (Supplemental Figure 
S1A).  
 
Pluripotent stem cell-derived hiHeps develop apical-basolateral polarity and 
form branching bile canalicular networks 
The canalicular multispecific organic anion transporter 1 (cMOAT1/ABCC2) revealed 
the presence of branching networks of canaliculi running between adjacent mature 




ERM-family proteins including the dominant ERM-protein in hepatocytes, radixin, 
which is considered a structural marker of bile canaliculi [31] (Figure 3B-C).  
ABCC2 was exclusively localized to the canalicular domain (Figure 3B), flanked by 
the tight junction-associated protein ZO-1 (Figure 3C) [32], indicating that hiHeps 
developed canalicular-sinusoidal polarity. Three-dimensional reconstruction 
supported the lateral orientation of the canaliculi (Figure 3E), a hallmark of 
hepatocytes in the liver [1]. Other canalicular proteins including bile salt export pump 
(BSEP/ABCB11) and 5’nucleotidase (NT5E) were also restricted at the canalicular 
domain (Figure 3F). By contrast, anoctamin-6 (ANO6) was observed at both the 
apical and basolateral surface domains (Figure 3F), as in vivo. The fluorescent 
ABCC2 substrate 5-chloromethylfluorescein (CFDA) [31] was secreted and retained 
in the canaliculi of living hiHeps (Figure 3F), supporting the luminal nature of the bile 
canaliculi. Electron-microscopy confirmed the presence bile canaliculi with microvilli 
and associated tight junctions (Figure 3G). Notably, all hiHeps that formed bile 
canaliculi expressed the AAT protein (Figure 3D, Supplemental Figure S1C), 
indicating that these represented well-differentiated hiHeps. Together, human 
pluripotent stem cell-derived hiHeps developed apical-basolateral polarity and formed 
bile canaliculi.   
 
Polarized hiHeps recapitulate polarized trafficking processes 
To investigate whether the polarized hiHeps recapitulated regulated polarized 
trafficking processes, we examined the ability of copper to trigger the redistribution of 
the copper transporter ATP7B from TGN to the canalicular domain [3,12,33]. During 




(Figure 4A). In mature hiHeps ATP7B colocalized with the TGN marker Golgin-97 
(Figure 4B) and was absent from the ABCC2-labeled canaliculi (Figure 4C,D) under 
copper-chelated conditions. Copper-treatment resulted in reduced ATP7B 
colocalization with Golgin-97 (Figure 4B) and its appearance at the ZO-1-bordered 
canaliculi (Figure 4C-D). ATP7B in copper-treated hiHeps also appeared at LAMP1-
positive compartments (Figure 4E), which have been implicated in the trafficking of 
ATP7B to the bile canaliculi [12,23] although debated [34]. Fluorescence intensity 
boxplots covering the intracellular ATP7B compartments and the canalicular domain 
illustrated ATP7B translocation by the appearance of overlapping ABCC2 and ATP7B 
peaks in the copper-treated conditions (Figure 4F). To obtain a measure of ATP7B 
canalicular translocation that was representative of the population as a whole, these 
intensity plots were used to determine the relative ATP7B intensity at the maximum 
relative intensity of ABCC2 for multiple canaliculi. Resultant dotplots showed that in 
copper-treated hiHeps, ATP7B staining is significantly more intense at the canalicular 
domain for the majority of canaliculi, when compared to BCS-treated controls (Figure 
4G).  
Pluripotent stem cells can also be generated by reprogramming somatic cells from 
any individual. The differentiation of these induced pluripotent stem cells (iPSC) from 
healthy individual’s somatic cells to hiHeps (Control-1) yielded similar results when 
compared to HUES9-derived hiHeps, including development of cell polarity and bile 
canaliculi (supplemental Figure S2A-B) and the copper-stimulated canalicular 
redistribution of ATP7B (Figure 5A-D).  
These data show that hiHeps not only developed apical-basolateral polarity and 
formed bile canaliculi, but also recapitulated regulated polarized trafficking 





Endogenously expressed mutant ATP7B-H1069Q shows defective copper-
stimulated redistribution to the bile canalicular domain 
The ability of iPSC-derived hiHeps to develop apical-basolateral polarity, form bile 
canaliculi and recapitulate regulated polarized trafficking processes allowed us to for 
the first time characterize the polarized trafficking phenotype of endogenously 
expressed mutant ATP7B proteins. We generated urine cell-derived iPSC 
(supplemental Figure S3A-C) and thereof derived hiHeps of a WD patient (WD1) who 
presented advanced liver fibrosis at age 13 and has a compound heterozygous 
nonsense W779X and missense H1069Q mutation in the ATP7B gene. This was 
confirmed in the patient’s iPS (supplemental Figure S4A). H1069Q is the most 
common ATP7B mutation in the Caucasian WD population and presumed to lead to 
folding defects and retention of the mutant protein in the endoplasmic reticulum (ER) 
and its degradation [35]. The also common nonsense W779X mutation causes 
depletion of the protein. In accordance, Western blot analysis revealed the presence 
of a single band at the molecular weight of ATP7B and no truncated products in the 
WD hiHeps (Figure 6A).  
ATP7B expression was lower in WD hiHeps when compared to control hiHeps 
(Figure 6A,B). The protein reduction exceeded mRNA reduction (Figure 6C), 
supporting the previously reported increased degradation rate of ATP7B-H1069Q 
[23]. Importantly, WD and HUES9 showed similar differentiation yields, as 
determined by the percentage of AAT- and HNF4a-expressing hiHeps (Supplemental 
Figure S1A). Further, WD hiHeps developed apical-basal polarity and bile canaliculi, 
indicating that functional ATP7B is not essential for hepatocyte polarity (Figure 6F). In 




chelated culture conditions (Figure 6D, supplemental Figure S5A), indistinguishable 
from HUES9 cell-derived hiHeps (c.f., Figure 4B) and iPSC-derived hiHeps of control 
individuals (c.f., Figure 5A). Quantitative colocalization analyses revealed no 
difference between the extent of ATP7B or ATP7B-H1069Q colocalization with the 
TGN (supplemental Figure S5B).  However, in striking contrast to control iPSC- and 
HUES9-derived hiHeps, exposure of WD hiHeps to copper failed to trigger the 
redistribution of ATP7B-H1069Q to the canalicular domain (Figure 6F-H, 
respectively). Similar results were obtained with hiHeps derived from iPSC of an 
unrelated WD patient (WD2) with homozygous H1069Q/H1069Q mutations. Thus, 
hiHeps of this patient confirmed the significant localization of the endogenous 
ATP7B-H1069Q mutant protein at the TGN [25] (Supplemental Figure S7A) and the 
failure of the mutant protein to redistribute to the canaliculi in response to copper 
(Supplemental Figure S6C-E). Importantly, in hiHeps of a first-degree family member 
of this patient (Control-2) the copper-induced redistribution of ATP7B to the bile 
canaliculus was unaffected (Supplemental Figure S6A,B,E), indistinguishable from 
the unrelated control subject (c.f., Figures 4 and 5). Notably, while copper stimulated 
the redistribution of ATP7B-H1069Q to LAMP1-positive compartments in hiHeps of 
the homozygous patient (Supplemental Figure S7C), this was not observed in hiHeps 
of the heterozygous H1069Q/null patient (Figure 6E). These results reveal, for the 
first time, the trafficking phenotypes of endogenously expressed mutant ATP7B 
proteins in polarized hepatocytes. They demonstrate that the H1069Q mutation in 
ATP7B protein does not per se preclude the endogenous mutant protein from 
reaching a steady-state distribution at the TGN but, unexpectedly, causes a defect in 





Curcumin and 4-phenylbutyrate do not restore copper-induced canalicular 
translocation of ATP7B-H1069Q  
Earlier studies have demonstrated that ATP7B-H1069Q when overexpressed in cells 
or present in homozygous patient tissue can be retained in the ER, which precludes 
its trafficking to and function at the TGN and its copper-induced redistribution to the 
bile canaliculi. The pharmacological folding chaperones curcumin and 4-
phenylbutyrate have been reported to improve the folding, stability and trafficking of 
ER-retained ATP7B-H1069Q to the TGN [36]. Whether curcumin and 4-
phenylbutyrate can also restore the redistribution of TGN-resident ATP7B-H1069Q to 
bile canaliculi in response to high copper levels has not been experimentally 
addressed [36]. In curcumin-treated WD hiHeps, ATP7B-H1069Q maintained its 
predominant TGN localization and no copper-triggered redistribution to the canaliculi 
was observed (Figure 7A-B). Comparable results were obtained with 4-
phenylbutyrate (Figure 7A-B). Western blot analysis revealed that curcumin treatment 
of WD hiHeps expressing the endogenous mutant ATP7B-H1069Q protein led to a 
1.5-fold increase in the expression of ATP7B-H1069Q (Figure 7C), which is 
commonly interpreted to reflect improved stability of the mutant protein [22,36]. Our 
results suggest that curcumin and 4-phenylbutyrate may not be suitable to restore 
ATP7B-H1069Q trafficking in all patients and demonstrate the importance of 
investigating the usefulness of therapeutic compounds in the context of patient-
specific, autologous ATP7B mutant proteins.           
 
AP1S1 mutations do not preclude copper-induced canalicular translocation of 




Copper overload has been reported in patients with MEDNIK syndrome who have no 
mutations in ATP7B but mutations in the AP1S1 gene [37]. Whether copper overload 
in MEDNIK patients is due to a  ATP7B localization or trafficking defect, as suggested 
[34,38], has not been determined. We generated iPSC lines from a MEDNIK patient 
(Supplementary Figure S3A-C and S4B) and differentiated these to hiHeps. Our data 
show that in MEDNIK hiHeps under control conditions, ATP7B predominantly 
localized at the TGN (Figure 8A). No redistribution of ATP7B to other cellular 
locations or the canalicular domain was observed under control conditions. Copper 
exposure caused ATP7B redistribution to LAMP1-positve vesicles (Figure 8B) and to 
the canalicular domain (Figure 8C-E), indistinguishable from copper-exposed control 
hiHeps (c.f., Figure 4D-G and 5B-D). No accumulation of ATP7B was observed at 
other subcellular locations, which would be indicative for ATP7B missorting. Thus, 
the MEDNIK AP1S1 mutation, as such, does not necessarily change the subcellular 






We report a stem cell-based model system that reiterates the (dys)functionality of 
endogenously expressed mutant proteins in the context of the polarized hepatocyte, 
their associated diseases and treatment responses. We show that pluripotent stem 
cells can be differentiated to hepatocyte-like cells (hiHeps) that 1) develop an in vivo-
like branching canalicular network flanked by tight junctions, 2) establish a polarized 
distribution of bile canalicular membrane proteins at the apical surface domain, 3) 
secrete and retain bile canalicular efflux pump substrates in the canalicular lumen 
and, 4) display regulated polarized trafficking as exemplified by the copper-stimulated 
redistribution of ATP7B to the canalicular domain. Polarized iPSC-derived hiHeps 
offer a major advance over currently available hepatocyte model systems [39] as they 
allow the study of human patient-specific and endogenously expressed mutant 
proteins (homozygous or (compound) heterozygous) in easy to obtain and unlimited 
cultures of patient-own cells.   
We have applied iPSC-derived hiHeps to investigate the phenotype of the most 
frequent ATP7B mutation, H1069Q, in the Caucasian WD population [9], of which the 
functional consequences for the protein remain enigmatic [4]. Contrasting previous 
studies in which ATP7B-H1069Q was overexpressed and found retained in the ER, 
our data show that endogenously expressed ATP7B-H1069Q at low copper levels  
localized at the TGN, indistinguishably from wild-type ATP7B. Possibly, there is a 
critical expression level of the mutant protein beyond which the chaperone-based 
protein quality control machinery, which can suppress the unfolding propensity of 
(mutant) proteins [40], becomes overwhelmed. This could result in the ER retention 
of superfluous mutant proteins. Such scenario is in line with the reported role of the 




pharmacological chaperones 4-phenylbutyrate and curcumin to suppress ER 
retention of ATP7B-H1069Q [36] in conditions where the mutant protein was 
overexpressed in cell lines. While the influence of the protein quality control capacity 
and other putative genetic modifiers [43–45] on endogenous ATP7B-H1069Q stability 
and trafficking deserves further studies, our work and that of Parisi and colleagues 
[23] clearly demonstrate that the H1069Q substitution in ATP7B per se does not 
preclude its trafficking to the TGN. 
While the predominant ER retention of ATP7B-H1069Q when overexpressed in cell 
lines prohibited studies with regard to its copper-stimulated post-TGN and polarized 
trafficking behavior, our experiments with endogenously expressed ATP7B-H1069Q 
in polarized WD hiHeps now clearly demonstrate that the H1069Q mutation inhibited 
the copper-stimulated redistribution of ATP7B to the bile canalicular domain. 
Furthermore, treatment of the WD hiHeps with the folding chaperones curcumin or 4-
phenylbutyrate, which can improve the stability and TGN residence of ATP7B-
H1069Q under conditions where this mutant was trapped in the ER [36], failed to 
restore copper-stimulated redistribution of the endogenously expressed ATP7B-
H1069Q to the bile canalicular domain.  
Our results indicate that the disease mechanism in WD patients with the H1069Q 
mutation involves, in addition to the reduced expression of the mutant protein [25], a 
defect in the copper-stimulated redistribution of the non-degraded mutant protein to 
the canalicular domain. Importantly, as our findings suggest that curcumin and 4-
phenylbutyrate are not likely to be effective therapeutics to promote canalicular 
translocation of ATP7B-H1069Q, this study underscores the potential of personalized 
preclinical in vitro model systems for the evaluation of drug efficacy, especially in the 




In addition to mutations in ATP7B itself, mutations in genes that control ATP7B 
trafficking may also give rise to liver copper overload. We previously demonstrated 
that MEDNIK syndrome patients showed copper metabolism perturbations and 
hepatopathy, and MEDNIK fibroblasts showed aberrant intracellular trafficking of 
Menkes protein ATP7A [10]. The MEDNIK disease-causing gene AP1S1 encodes the 
sigma-1 subunit of an adaptor protein complex that mediates the sorting of 
membrane proteins with a cytoplasmic (D/E)XXXL[L/I] signal. Like ATP7A, ATP7B 
contains such a signal [47] which has led to suggest that the observed copper 
overload in MEDNIK patients results from defective ATP7B trafficking to the bile 
canaliculi [34,38]. We now demonstrate that hiHeps that endogenously express the 
disease-causing mutations in the AP1S1 gene do not show defects in the copper-
stimulated redistribution of ATP7B to the canalicular domain in MEDNIK HiHeps. This 
suggests that the copper metabolism perturbation and hepatopathy in this particular 
MEDNIK patient may not be caused by defective ATP7B trafficking in hepatocytes.  
In conclusion, investigating patient-derived polarized hiHeps that endogenously 
express disease-causing mutant genes and proteins revealed unexpected and new 
trafficking phenotypes of the ATP7B protein, as a function of mutations in AP1S1 and 
as a function of the H1069Q mutation in ATP7B. The results demonstrate the 
importance of investigating the (dys)functionality of endogenously expressed mutant 
proteins and their response to novel therapeutic strategies in patient-own cells in 
which the disease-causing mutant gene is endogenously expressed. The polarity and 
bile canaliculi-forming capacity of iPSC-derived hiHeps, as reported in this study, is 
an important step forward for the study of severe and incurable inherited liver 
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Figure 1. Differentiating HUES9 cells progressively acquire hepatic markers 
during directed differentiation to hiHeps 
(A) Schematic overview of differentiation protocol  with phase-contrast images of 
cells at each differentiation step. (B) Fluorescence microscopy images of different 
hiHep differentiation stage markers. Scale: 10µM. 
 
Figure 2.  Mature hiHeps express key hepatic markers and show capability of 
glycogen storage and LDL internalization 
(A) Fluorescence microscopy images of glutamine ligase (GLUL), Carbamoyl-
phosphate synthase 1 (CPS1), NTCP, AAT and internalized DiI-LDL. Scale bar of 
NTCP and AAT stainings: 10µM. (B) Western blot analysis of undifferentiated HUES9 
(S0) and hiHeps (S4) showing expression of pluripotency and hepatocyte markers. 
(C) Electron microscopy show the presence of glycogen in hiHeps. Yellow box and 
arrow (left image) indicate magnified area depicting cytosolic glycogen (right image). 
 
Figure 3. HiHeps form branching bile canalicular networks 
(A) Fluorescence microscopy images of ABCC2 at subsequent differentiation stages. 
Scale bar: 10µM. (B-E) Fluorescence microscopy images of ABCC2, radixin, ERM 
proteins and ZO-1 at bile canaliculi. Co-staining of ABCC2 and AAT demonstrate 
maturity of polarized hiHeps (Figure 3D). Orthogonal views of 3D imaged bile 
canaliculi reveal the lateral orientation of the canaliculi (Figure 3E, right side, top). 




right side, middle and bottom). Dashed line represents the author’s interpretation of a 
possible cell membrane arrangement not based on staining data. Dashed yellow line 
indicates orthogonal section plane. TJ: tight junction. BC: bile canaliculus. Scale bars: 
10 µM (F) Fluorescence microscopy images of ANO6, BSEP and 5’Nucleotidase 
(NT5E) at the BC in hiHeps. In addition, hiHeps transported the fluorescent ABCC2 
substrate CFDA into BC lumens. White arrows: apical ANO6, yellow arrowheads: 
basolateral ANO6. Scale bars: 10µM (G) Electron microscopy showing small lumens 
with villi  (white arrows) between hiHeps, which display microvilli formation at the 
apical surface enclosed by tight junctions (yellow arrowheads) and desmosomes (red 
arrowhead). 
 
Figure 4. Polarized HUES9-derived hiHeps recapitulate copper-stimulated 
ATP7B translocation  
(A) Fluorescence microscopy images of ATP7B in the subsequent differentiation 
stages. (B) Fluorescence microscopy images of ATP7B and Golgin97 (B), ATP7B 
and ZO-1 (C),  ATP7B and ABCC2  (D), and ATP7B and LAMP1  (E) in mature BCS-
treated (white arrows) and CuSO4-treated (white arrows) HUES9-derived hiHeps in 
BCS, white arrows). Scale bars: 10µM. Yellow arrowhead indicates ATP7B at the 
BC.  Scale bars: 10µM  (F) Fluorescence intensity profile plots along the polarization 
axis (areas indicated by yellow brackets in Figure 3D, yellow arrows indicate plot 
direction) showing overlapping ABCC2 and ATP7B intensity peaks in copper treated 
hiHeps but not in control. (G) Graph depicting the percentage values of ATP7B 
intensity at which the ABCC2 intensity is at its maximum (e.g. 3.8% for BCS condition 




standard error of the mean. Asterisks indicate statistical significance (P <0.001) 
based on Mann–Whitney U test.   
 
Figure 5. HiHeps derived from healthy control iPSC recapitulate copper-
stimulated ATP7B translocation  
 (A-B) Fluorescence microscopy images of ATP7B and Golgin-97 (A) and ATP7B and 
ABCC2 (B) in BCS-treated and copper-treated control iPSC derived hiHeps (Control-
1). Scale bars: 10µM. (C) Fluorescence intensity profile plots along the polarization 
axis  (areas indicated by yellow brackets in Figure 3D, yellow arrows indicate plot 
direction) showing clear overlap of ABCC2 and ATP7B intensity peaks in copper 
treated hiHeps, but not in control.  (D) Graph depicts the percentage values of 
ATP7B intensity at which the ABCC2 intensity is at its maximum (12.3% for BCS 
condition and 85.7% for CuSO4 condition in figure 5B) for multiple BCs. Error bars 
indicate SEM. Asterisks: significance (p<0.001) based on Mann–Whitney U-test.   
 
Figure 6. Mutant ATP7B-H1069Q localizes to the TGN but does not translocate 
to the canalicular domain upon copper exposure 
(A) Blot of WD1 H1069Q/W779X hiHeps showing expression of ATP7B-H1069Q of 
wildtype length. No ATP7B-W779X expression was observed. Note that the ATP7B 
antibody epitope is located before the W779 and an 80kDA band is expected for the 
truncated product. (B) Quantification of three independent WD1 hiHeps ATP7B blots 
relative to Hues9. Significance testing of WD1 column was done to a hypothetical 
value of 1. (C) Relative expression of ATP7B mRNA in Hues9 and WD1 hiHeps. (D-




H1069Q and LAMP1  (E), ad ATP7B-H1069Q and ABCC2 (F) in BCS- and copper-
treated WD iPSC derived hiHeps (BCS and CuSO4, white arrows). Scale bars: 
10µM. (G) Fluorescence intensity profile plots along the polarization axis (areas 
indicated by yellow brackets, yellow arrows indicate plot direction) showing no 
overlap of ABCC2 and ATP7B intensity peaks in copper-treated hiHeps. (H) Graph 
depicting the percentage values of ATP7B intensity at which the ABCC2 intensity is 
at its maximum (e.g. 24.1% for BCS condition and 3.6% for CuSO4 condition in figure 
6D) for multiple WD H1069Q/W779X  hiHep BC’s. Error bars indicate standard error 
of the mean. No significant difference was observed between means of BCS and 
CuSO4 conditions (p= 0.445 based on Mann–Whitney U-test). 
 
Figure 7. Curcumin and 4-phenylbutyrate do not restore copper-induced 
canalicular translocation of ATP7B-H1069Q 
(A) Fluorescence microscopy images of ATP7B/H1069Q and ABCC2 in curcumin- or 
4-PBA-pretreated and copper-treated WD hiHeps and hereof derived fluorescence 
intensity plots (plot areas indicated by yellow brackets, yellow arrows indicate plot 
direction). (B) Graph depicting the percentage values of ATP7B intensity at which the 
ABCC2 intensity is at its maximum for multiple BC in each condition. Note: HUES9 
data points are the same as depicted in figure 4G and data points from BCS and 
CuSO4 conditions are the same as depicted in figure 6F. No significant difference 
was observed upon PBA treatment compared to CuSO4 alone (p=0.126 )Mann–
Whitney U-test), or upon curcumin treatment compared to CuSO4 alone (p=0.227 
(Mann–Whitney U-test). (C) Blot showing ATP7B-H1069Q expression in  curcumin-
treated hiHeps and graph depicting quantification of ATP7B-H1069Q signal relative 





Figure 8. Copper stimulates ATP7B redistribution to the canalicular domain In 
MEDNIK syndrome hiHeps  
(A-C) Fluorescence microscopy images of ATP7B and Golgin-97 (A), ATP7B and 
LAMP1 (B), ATP7B and ABCC2 (C) in BCS-treated and copper-treated MEDNIK 
hiHeps. Scale bars: 10µM.  (D) Fluorescence intensity profile plots along the 
polarization axis (areas indicated by yellow brackets, yellow arrows indicate plot 
direction) showing overlapping ABCC2 and ATP7B intensity peaks in copper treated 
hiHeps, but not in control. (E) Graph depicting the percentage values of ATP7B 
intensity at which the ABCC2 intensity is at its maximum for multiple BCs. Error bars 






 Functional cell polarity can be achieved in patient pluripotent stem cell-derived 
hepatocytes, which allows the study of autologous mutant proteins in biliary 
processes. 
 The most frequent Wilson disease-causing ATP7B-H1069Q mutation prevents 
its copper-induced polarized redistribution to the bile canalicular domain. 
 MEDNIK syndrome-causing AP1S1 gene mutations do not cause the 
expected defect in the copper-stimulated redistribution of ATP7B to the 
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